Login / Signup

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.

Marcelo C PasquiniPaul K WallaceBrent R LoganManmeet KaurJoseph D TarioAlan HowardYali ZhangClaudio BrunsteinYvonne EfeberaNancy L GellerSergio A GiraltParameswaran N HariMary M HorowitzJohn KorethAmrita Y KrishnanHeather J LandauGeorge SomloNina ShahEdward StadtmauerDan T VoglDavid H VesolePhilip L McCarthyTheresa Hahn
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.
Keyphrases
  • multiple myeloma
  • stem cell transplantation
  • newly diagnosed
  • bone marrow
  • cell therapy
  • chronic lymphocytic leukemia
  • mesenchymal stem cells
  • free survival
  • high dose